drugset / Trial / NCT05411900

BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome

NCT05411900 ↗

Phase 2 Unknown 164 enrolled Francesco Bono
RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of the study is to assess the safety and efficacy of repeated administrations of BoNT-A in subjects with NP attributable to carpal tunnel syndrome (CTS) through a randomized, double-blind, placebo-controlled study. Further research has shown that BoNT-A has analgesic properties independently from its action on muscle tone, possibly by acting on neurogenic inflammation. Therefore, the study drug may be better than other treatments surgical or non-surgical currently available for the treatment of CTS.

Timeline

Start
2022-05-25
Primary completion
2023-12
Completion
2023-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BoNT-A Protein / enzyme biologic 333 iu Other